Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 56Squamous Cell Carcinoma of Head and Neck 31Lung Neoplasms 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Carcinoma, Transitional Cell 8Neoplasm Metastasis 7Mouth Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Recurrence 6Neoplasms 6Melanoma 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 6Mesothelioma, Malignant 5Medulloblastoma 5Laryngeal Neoplasms 5

Interventions

Gemcitabine 3Cisplatin 3Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1atezolizumab 1Tiragolumab 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Urothelial Cancer × Cisplatin × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT02516241 2026-04-20

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

AstraZeneca

Phase 3 Active not recruiting
1,126 enrolled 52 charts
Genitourinary

Urothelial Cancer

NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡